Production of a Novel OX40 Ligand for Clinical Use

Abstract

Cancer cells have evolved to evade immune-mediated destruction through several documented mechanisms. Our group has developed a technique to enhance immune function in tumor-bearing hosts by targeting a protein on the surface of white blood cells, termed OX40. This type of immune modulation leads to therapeutic benefit in tumor-bearing mice. We have produced a protein that binds to the human OX40 protein and activates human white blood cells. We have a cell line that produces high quantities of this protein and our goal is to test this protein for safety and efficacy in non-human primates so that we can obtain FDA approval for clinical trials in cancer patients. The long-range goal of this proposal is translate these findings to prostate cancer patients.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2014
Accession Number
ADA614102

Entities

People

  • Andrew D. Weinberg

Organizations

  • Providence Portland Medical Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Blood
  • Blood Cells
  • Cell Line
  • Cells
  • Chemistry
  • Clinical Trials
  • Department Of Defense
  • Leukocytes
  • Lymphocytes
  • Neoplasms
  • Production
  • Prostate
  • Prostate Cancer
  • Proteins
  • Tissue Culture

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Molecular and Cellular Biochemistry
  • Oncology (Cancer Research).